India markets close in 2 hours 5 minutes

Astellas Pharma Inc. (ALPMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
17.53+0.13 (+0.75%)
At close: 3:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.40
Open17.52
Bid0.00 x 0
Ask0.00 x 0
Day's range17.51 - 17.61
52-week range13.41 - 17.78
Volume85,109
Avg. volume78,263
Market cap32.601B
Beta (5Y monthly)0.63
PE ratio (TTM)29.66
EPS (TTM)0.59
Earnings dateN/A
Forward dividend & yield0.39 (2.26%)
Ex-dividend date29-Mar-2021
1y target estN/A
  • Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
    Business Wire

    Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

    Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced updated results from two clinical trials examining PADCEV® (enfortumab vedotin-ejfv) alone (EV-201 Cohort 2) and PADCEV in combination with Merck’s (known as MSD outside the United States and Canada) KEYTRUDA® (pembrolizumab) (EV-103 Cohort A) in patients with locally advanced or metastatic urothelial cancer who are not able to receive cisplatin chemotherapy.

  • Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review
    Zacks

    Seagen's (SGEN) Two sBLAs for Padcev Gets FDA Priority Review

    The FDA accepts Seagen (SGEN) and Astellas' two sBLAs for Padcev under a priority review to treat patients with locally advanced or metastatic urothelial carcinoma. A verdict is pending on Aug 17, 2021.

  • European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
    Business Wire

    European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin

    Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that a marketing authorization application (MAA) for enfortumab vedotin was accepted by the European Medicines Agency (EMA). The MAA requests review of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in the European Union for people living with urothelial cancer.